Lipid News

Variety is not a spice
for some lipids!

Daniel M. Raben Richard Epand
By Daniel M. Raben and Richard Epand
Jan. 1, 2015

We all learn that phospholipids are composed of glycerol, to which fatty acids and a defining head group are attached. We also know that many phospholipids have a characteristic set of attached fatty acids. Why such specificity exists and which physiological roles they play has eluded us. In this month’s Lipid News article, Richard Epand of McMaster University describes his recent work that uncovered how this enrichment is achieved for the important signaling lipids called phosphoinositides.

Fatty-acid composition in phospholipids sometimes happens after their synthesis, at which point the attached fatty acids are exchanged for other fatty acids in a process known as remodeling. For the phosphoinositides, the selectivity occurs not only via remodeling after the synthesis of the phospholipid but also during their synthesis. These phospholipids are enriched heavily with a select set of fatty acids called stearic acid and arachidonic acid. Epand’s lab showed that two important enzymes involved in their synthesis, diacylglycerol kinase-epsilon and cytidine diphosphate synthease-2, prefer precursor substrates with the selected fatty acids. Epand’s article describes new findings regarding how fatty-acid selectivity is achieved for other lipids as well.

These studies offer us a glimpse of the mechanisms of fatty-acid specificity within lipid classes. Why is this important? What role do select fatty acids play in physiological processes? We now may be in a better position to start answering these questions. – Daniel Raben

Enrichment of acyl chains in the lipids of the phosphatidylinositol cycle

By Richard Epand

Phosphorylated forms of phosphatidylinositol play important roles in signaling and cell function. It has been known for many years that these lipids are synthesized in the phosphatidylinositol cycle and are highly enriched with 1-stearoyl-2-arachidonoyl species. Several mechanisms contribute to this enrichment including the remodeling of synthesized phospholipids through the action of acyl transferases (the Lands pathway) as well as through the specificity of the enzymes of the phosphatidylinositol cycle (see figure).

In the phosphatidylinositol cycle, a diacylglycerol kinase phosphorylates diacylglycerol. Although there are 10 different diacylglycerol kinase isoforms in mammals, in addition to gene-splice variants, one isoform called DGKε shows specificity for diacylglycerol species that reflect the acyl chains found in phosphatidylinositol. The phosphatidic acid product of DGKε catalysis is then converted to CDP-diacylglycerol (CDP-DAG), catalyzed by the enzyme CDP-DAG synthase, known as CDS.

CDS2, one of the two isoforms of mammalian CDS, also exhibits acyl-chain specificity for its substrate phosphatidic acid, favoring 1-stearoyl-2-arachidonoyl species, like DGKε

It is important that the phosphatidylinositol cycle describes a cyclical metabolic pathway so that the intermediates of the cycle are regenerated each time the cycle goes around. As a consequence, the preferential incorporation of particular acyl chains at one step in the cycle would be magnified because of progressive enrichment in each cycle. The lipid intermediates of the cycle have to be segregated from other forms in the cell, because most species of these intermediates would not be enriched with 1-stearoyl-2-arachidonoyl species. This segregation is difficult to achieve, because different steps of the cycle occur in two different membranes: the plasma membrane and the endoplasmic reticulum. This is a current area of research.

Once phosphatidylinositol is formed, the acyl-chain enrichment with 1-stearoyl-2-arachidonoyl species does not change much in forming PI4P and PIP2 (see figure). In addition, we find that conversion of CDP-DAG to phosphatidylinositol, catalyzed by phosphatidylinositol synthase, or PIS for short, does not result in acyl-chain enrichment. Therefore, only two enzymes – DGKε and CDS2 – are principally responsible for acyl-chain enrichment. We suggest that the extent of acyl-chain enrichment with 1-stearoyl-2-arachidonoyl species depends to a large extent on the level of expression of these isoforms in different organs.

Interestingly, the enzyme PIS, which does not exhibit acyl-chain preference, is expressed in only one form. In contrast, there are multiple isoforms for DGK and CDS, only one of which shows acyl-chain specificity. Hence, when the availability of arachidonic acid, an essential fatty acid, is low or the expression of DGKε or CDS2 is low, phosphatidylinositol synthesis still can continue with the substitution of other isoforms of DGK or CDS.

Other organisms have phosphatidylinositol species that are different from the 1-stearoyl-2-arachidonoyl forms found in mammals. Plants have mostly linoleic acid at the sn-2 position. The two major phosphatidylinositol species in yeast are 34:1 and 32:1, making up 56 percent of the phosphatidylinositol In the case of the Amoebozoa, Dictyostelium discoideum, the major phosphatidylinositol species, is an ether-linked lipid 1-hexadecyl-2-(11Z-octadecanoyl)-sn-glycero-3-phospho-(1’-myo-inositol). It appears that the phosphatidylinositol of Dictyostelium discoideum is not formed from diacylglycerol through the phosphatidylinositol cycle but rather from phosphatidic acid.

All eukaryotes have only one or a few species of phosphatidylinositol with particular hydrocarbon chains. This observation suggests that the hydrocarbon chains of phosphatidylinositol and its phosphorylated species are important to their functions. Specific acyl chains on other lipids also may be required for specific functions. We are just beginning to unravel the mechanisms by which hydrocarbon chain specificity determines physiological function.

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
Daniel M. Raben
Daniel M. Raben

Daniel M. Raben is a professor at the Johns Hopkins University School of Medicine and a 2021 ASBMB fellow.

Richard Epand
Richard Epand

Richard Epand is a professor at McMaster University in Canada.

Related articles

At the interface
Lina M. Obeid & Michael J. Pulkoski-Gross
Targeting cardiolipin modification in a genetic disorder
Arianna F. Anzmann, Olivia Sniezek & Hilary Vernon
A versatile lipid second messenger
Hui Liu & Alex Toker
Unexpected roles of lipid kinases
Kaoru Goto & Toshiaki Tanaka

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Seeking the sweet spot to beat a pig parasite
Journal News

Seeking the sweet spot to beat a pig parasite

July 16, 2024

Researchers extracted, separated and tested glycans from the porcine whipworm in an effort to determine the best way to develop treatments and vaccines.

Radioactive drugs strike cancer with precision

Radioactive drugs strike cancer with precision

July 14, 2024

The tumor-seeking radiopharmaceuticals are charting a new course in oncology, with promise for targeted treatments with fewer side effects.

Animals have used bioluminescence to communicate for millions of years

Animals have used bioluminescence to communicate for millions of years

July 13, 2024

Despite its widespread occurrence, scientists don’t yet know when or where this phenomenon first emerged, or its original function.

Getting to the genetic basis of cardiovascular disease
Journal News

Getting to the genetic basis of cardiovascular disease

July 11, 2024

Edwin G. Peña Martínez received a JBC Tabor award for associating the condition with mutations in noncoding sequences.

Microparticles safeguard vitamins and information

Microparticles safeguard vitamins and information

July 9, 2024

Scientists aim to use nanotechnology to combat malnutrition and improve medical recordkeeping in impoverished parts of the world.

Why AlphaFold 3 needs to be open source

Why AlphaFold 3 needs to be open source

July 7, 2024

The powerful AI-driven software from DeepMind was released without making its code openly available to scientists.